Additional Information

Description

Triumeq® is a fixed-dose combination tablet containing abacavir sulfate, dolutegravir sodium, and lamivudine. This formulation combines three antiretroviral agents to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI), lamivudine is also an NRTI, and dolutegravir is an integrase strand transfer inhibitor (INSTI).

Abacavir and lamivudine inhibit reverse transcriptase, blocking the conversion of viral RNA into DNA, while dolutegravir inhibits integrase, preventing the integration of viral DNA into the host genome. This combination therapy helps to reduce the viral load, increase CD4 cell counts, and maintain virologic suppression in patients with HIV-1.

Each tablet is administered orally once daily, with or without food. Triumeq® is prescribed as part of a comprehensive treatment regimen for HIV-1 and offers the convenience of a single, once-daily tablet, improving patient adherence to the treatment plan. Common side effects include headache, diarrhea, and fatigue.